AU2012240131B2 - Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow - Google Patents

Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow Download PDF

Info

Publication number
AU2012240131B2
AU2012240131B2 AU2012240131A AU2012240131A AU2012240131B2 AU 2012240131 B2 AU2012240131 B2 AU 2012240131B2 AU 2012240131 A AU2012240131 A AU 2012240131A AU 2012240131 A AU2012240131 A AU 2012240131A AU 2012240131 B2 AU2012240131 B2 AU 2012240131B2
Authority
AU
Australia
Prior art keywords
cerebral
sterile
calcium channel
therapeutic agent
subarachnoid space
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012240131A
Other languages
English (en)
Other versions
AU2012240131A1 (en
Inventor
Brian A. Leuthner
R. Loch Macdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDS Biotechnology Corp
Original Assignee
Edge Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edge Therapeutics Inc filed Critical Edge Therapeutics Inc
Publication of AU2012240131A1 publication Critical patent/AU2012240131A1/en
Application granted granted Critical
Publication of AU2012240131B2 publication Critical patent/AU2012240131B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012240131A 2011-04-05 2012-04-05 Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow Ceased AU2012240131B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161471779P 2011-04-05 2011-04-05
US61/471,779 2011-04-05
PCT/US2012/032317 WO2012138854A1 (en) 2011-04-05 2012-04-05 Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Publications (2)

Publication Number Publication Date
AU2012240131A1 AU2012240131A1 (en) 2013-10-17
AU2012240131B2 true AU2012240131B2 (en) 2017-07-20

Family

ID=46969546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012240131A Ceased AU2012240131B2 (en) 2011-04-05 2012-04-05 Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Country Status (13)

Country Link
US (2) US9364432B2 (cg-RX-API-DMAC7.html)
EP (1) EP2694133B1 (cg-RX-API-DMAC7.html)
JP (2) JP6336899B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140052992A (cg-RX-API-DMAC7.html)
CN (1) CN103517726B (cg-RX-API-DMAC7.html)
AU (1) AU2012240131B2 (cg-RX-API-DMAC7.html)
CA (1) CA2832501A1 (cg-RX-API-DMAC7.html)
GB (1) GB2513675A (cg-RX-API-DMAC7.html)
HK (1) HK1198933A1 (cg-RX-API-DMAC7.html)
IL (1) IL228539B (cg-RX-API-DMAC7.html)
RU (2) RU2606169C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201602665UA (cg-RX-API-DMAC7.html)
WO (1) WO2012138854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
EP3682912B1 (en) * 2012-08-17 2025-11-26 AMSilk GmbH Use of self-assembling polypeptides as tissue adhesives
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
RU2741629C2 (ru) 2016-09-20 2021-01-28 Бракко Дайэгностикс Инк. Системы и способы производства, инфузионного ввода и контроля доставки радиоактивного изотопа
US10646227B2 (en) 2016-12-29 2020-05-12 Cerepeutics, LLC Systems and methods for acute treatment to limit intracerebral hemorrhage growth
WO2019018306A1 (en) * 2017-07-17 2019-01-24 Edge Therapeutics, Inc. ADVANCED MICROPARTICULAR FORMULATIONS CONTAINING FORM 2 OF MICRONIZED POLYMORPHIC NIMODIPINE
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
CN112074917B (zh) 2018-03-28 2024-10-29 布拉科诊断公司 用γ检测器对放射性同位素递送系统进行校准的系统和技术
CN112106148B (zh) 2018-03-28 2024-10-29 布拉科诊断公司 放射性同位素发生器寿命的早期检测
CN115104159A (zh) 2020-02-21 2022-09-23 布拉科诊断公司 放射性同位素发生器早期突破检测
US12016774B2 (en) 2020-05-08 2024-06-25 Medtronic Vascular, Inc. Delivery system for prosthetic valve device having controlled release of inflow and outflow ends
RU2763254C1 (ru) * 2020-08-31 2021-12-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения церебрального вазоспазма при аневризматическом субарахноидальном кровоизлиянии
US11992642B2 (en) 2020-10-30 2024-05-28 Medtronic, Inc. Implantable medical device for delivery of pharmacological agents to the deep brain structures
US11745003B2 (en) 2020-10-30 2023-09-05 Medtronic, Inc. Implantable access port with one-directional filter
US11931545B2 (en) 2020-10-30 2024-03-19 Medtronic, Inc. Drug infusion port
US12551613B2 (en) 2020-10-30 2026-02-17 Medtronic, Inc. Implantable drug delivery port
US12226609B2 (en) 2020-12-16 2025-02-18 Medtronic, Inc. Method to detect inadvertent delivery of drug to a subcutaneous pocket

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993855A (en) * 1995-09-18 1999-11-30 Shiseido Company, Ltd. Delayed drug-releasing microspheres
US6358536B1 (en) * 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US20040105888A1 (en) * 2002-11-26 2004-06-03 Daniel Pratt Buoyant polymer particles for delivery of therapeutic agents to the central nervous system

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
CA2180526A1 (en) 1994-01-05 1995-07-13 Joseph C. Hogan, Jr. Method of identifying chemical compounds having selected properties for a particular application
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
ATE318580T1 (de) * 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
JP2000070366A (ja) 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
AU2607701A (en) 1999-12-29 2001-07-09 Regeneration Technologies, Inc. System for reconstituting pastes and methods of using same
JP2003520830A (ja) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション 再狭窄および吻合内膜過形成処置のための送達系
WO2003020208A2 (en) * 2001-08-31 2003-03-13 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
ATE470351T1 (de) 2001-11-22 2010-06-15 Japan Science & Tech Agency Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht
AU2003219922B2 (en) 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20060094643A1 (en) 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
JP4092994B2 (ja) 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EA012125B1 (ru) * 2005-05-24 2009-08-28 Утерон Фарма С.А. Двухкамерное смесительное устройство для вязких фармацевтических веществ
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20090156481A1 (en) 2005-07-15 2009-06-18 Novo Nordisk Healthcare A/G Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
US20070203079A1 (en) * 2005-11-21 2007-08-30 Caldwell Guy A Methods of using small molecule compounds for neuroprotection
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US8252302B2 (en) 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
NZ599430A (en) 2007-06-11 2014-03-28 Loch Macdonald R A drug delivery system for the prevention of cerebral vasospasm
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
JP2009067771A (ja) * 2008-05-27 2009-04-02 Pacira Pharmaceuticals Inc 神経学的疾患の治療方法
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
EP2331082B1 (en) 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
CA2737484C (en) 2008-09-18 2017-10-10 Surmodics Pharmaceuticals, Inc. Microencapsulation process with solvent and salt
JP2012515837A (ja) 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ, インコーポレイテッド 異なる非反復単位を有するポリマーを含むポリマー混合物、ならびにそれを作製および使用するための方法
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
US20100189763A1 (en) 2009-01-23 2010-07-29 Heather Nettles Controlled release systems from polymer blends
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
JP5791629B2 (ja) 2009-12-22 2015-10-07 エボニック コーポレイションEvonik Corporation 微粒子を調製する乳剤基調プロセス、及び、プロセスで利用されるワークヘッド構造体
JP2013523752A (ja) 2010-03-29 2013-06-17 エボニック デグサ コーポレイション 局所投与部位における医薬組成物の保持改善のための組成物および方法
PL2658024T3 (pl) * 2011-01-27 2022-12-05 Lg Energy Solution, Ltd. Taśma
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993855A (en) * 1995-09-18 1999-11-30 Shiseido Company, Ltd. Delayed drug-releasing microspheres
US6358536B1 (en) * 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US20040105888A1 (en) * 2002-11-26 2004-06-03 Daniel Pratt Buoyant polymer particles for delivery of therapeutic agents to the central nervous system

Also Published As

Publication number Publication date
EP2694133B1 (en) 2018-05-23
RU2606169C2 (ru) 2017-01-10
RU2013148938A (ru) 2015-05-10
JP6336899B2 (ja) 2018-06-06
IL228539B (en) 2018-10-31
US20160193198A1 (en) 2016-07-07
US9364432B2 (en) 2016-06-14
NZ714032A (en) 2017-03-31
AU2012240131A1 (en) 2013-10-17
KR20140052992A (ko) 2014-05-07
EP2694133A4 (en) 2014-11-19
CN103517726A (zh) 2014-01-15
RU2016144847A3 (cg-RX-API-DMAC7.html) 2018-05-17
SG10201602665UA (en) 2016-05-30
RU2016144847A (ru) 2018-05-17
CA2832501A1 (en) 2012-10-11
US20120245561A1 (en) 2012-09-27
NZ616458A (en) 2016-01-29
CN103517726B (zh) 2016-08-17
EP2694133A1 (en) 2014-02-12
HK1198933A1 (en) 2015-06-19
SG193991A1 (en) 2013-11-29
WO2012138854A1 (en) 2012-10-11
NZ727856A (en) 2018-06-29
JP2017036320A (ja) 2017-02-16
IL228539A0 (en) 2013-12-31
JP2014515744A (ja) 2014-07-03
GB2513675A (en) 2014-11-05
GB201317446D0 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
US9364432B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
US8303974B2 (en) Drug delivery system for the prevention of cerebral vasospasm
AU2012214137B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
AU2016201681B2 (en) A drug delivery system for the prevention of cerebral vasospasm
NZ714032B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ727856B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ616458B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
AU2013203192B2 (en) A drug delivery system for the prevention of cerebral vasospasm
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired